Selected Publications
1. Shah PA, Fernandez AM, Sambandam V, Zhao H, Mazumdar T, Shen L, Wang Q, Ahmed K, Frederick MJ, Wang J, Johnson FM. Sustained Aurora kinase B expression protects head and neck squamous cell carcinoma from PI3K inhibition-induced apoptosis Under Revision 2022
2. Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, Rawal S, Shah PA, El-Naggar AK, Johnson JM, Frederick MJ. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer. Oncologist. e-Pub 9/2022. PMID: 36124629
3. Ghosh S, Mazumdar T, Xu W, Powell RT, Stephan C, Shen L, Shah PA, Pickering CR, Myers JN, Wang J, Frederick MJ, Johnson FM. Combined TRIP13 and Aurora Kinase Inhibition Induces Apoptosis in Human Papillomavirus-Driven Cancers; Clinical Cancer Research, 2022 Aug 16. PMID: 35972731
4. Ghosh S, Shah PA, Johnson FM. Novel systemic treatment modalities including immunotherapy and molecular targeted therapy for recurrent and metastatic head and neck squamous cell carcinoma. Soma Ghosh, Pooja A. Shah, Faye M Johnson. International Journal of Molecular Sciences; 2022 Jul 17;23(14):7889. PMID: 35887235
5. Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM, Frederick MJ. NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. Cells 9(12), 12/2020. e-Pub 12/2020. PMCID: PMC7764697.
6. Singh R, Peng S, Viswanath P, Sambandam V, Shen L, Rao X, Fang B, Wang J, Johnson FM. Non-canonical cMet regulation by vimentin mediates Plk1 inhibitor-induced apoptosis. EMBO Mol Med 11(5), 5/2019. e-Pub 4/2019. PMCID: PMC6505578.
7. Sambandam V, Frederick MJ, Shen L, Tong P, Rao X, Peng S, Singh R, Mazumdar T, Huang C, Li Q, Pickering CR, Myers JN, Wang J, Johnson FM. PDK1 mediates NOTCH1-mutatedhead and neck squamous carcinoma vulnerability to therapeutic PI3K/mTORinhibition. Clin Cancer Res 25(11):3329-3340, 6/2019. e-Pub 2/2019. PMCID:PMC6548600.
8. Kalu N, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC and Johnson FM. Comprehensive Pharmacogenomic Profiling of Human Papillomavirus- Positive and -Negative Squamous Cell Carcinoma Identifies Sensitivity to Aurora Kinase inhibition in KMT2D Mutants. Cancer Letters, 2018, 431:64-72.
9. Viswanath P, Peng S, Singh R, Kingsley C, Balter PA, Johnson FM. A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia 20(10):975-984, 10/2018. e-Pub 8/2018. PMCID: PMC6111024.
10. Kalu N, Mazumdar T, Peng S, Shen L, Sambandam V, Rao X, Xi Y, Li L, Qi Y, Gleber- Netto F, Patel A, Wang J, Frederick MJ, Myers JN, Pickering CR and Johnson FM. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget, 2017. Sept 8(49): 86369-86383.
11. Zhang M, Singh R, Peng S, Mazumdar T, Sambandam V, Shen L, Tong P, Li L, Kalu NN, Pickering CR, Frederick M, Myers JN, Wang J, Johnson FM. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters, 2017, 392:71-82
12. Kalu NN, Johnson FM. Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? Expert Opin Investig Drugs 26(2):207-217, 2/2017. e-Pub 1/2017. PMID: 28042706.
13. Ferrarotto R, Goonatilake R, Young Yoo S, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Clin Cancer Res. e-Pub 11/2015. PMID: 26597303.
14. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM. Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib. Sci Transl Med 4(136):136ra70, 5/2012. PMID: 22649091
15. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol 28(30):4609-4615, 10/2010. e-Pub 9/2010. PMCID: PMC2974341.